A randomized, partially blind, placebo controlled, crossover, single oral dose study to assess the effect of concomitant antacid (calcium carbonate / magnesium hydroxide) on the pharmacokinetics and pharmacodynamics of SMC021 (0.8 mg Salmon calcitonin/200 mg 5-CNAC) in healthy postmenopausal women
Latest Information Update: 16 Nov 2012
At a glance
- Drugs Calcitonin (Primary) ; Calcium carbonate; Magnesium hydroxide
- Indications Postmenopausal osteoporosis
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Novartis
- 21 Jun 2007 Status change from in progress to completed
- 30 Jan 2007 New trial record.